Veteran biotech investors Steven St. Peter and Luke Evnin launched Vie Ventures to bridge traditional venture capital with disease-focused philanthropy to target autoimmune and immune-mediated diseases. The fund partners with large patient organizations, such as the Lupus Research Alliance and Scleroderma Research Foundation, to invest in series B and C rounds in clinical-stage companies. We spoke to St. Peter, co-founder and managing director of Vie Ventures, about the firm’s investment model, its initial focus on immune-mediated diseases, and its work with major patient organizations.